Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study
Konstantinos A Toulis1, Krishnarajah Nirantharakumar, Ronan Ryan
1Department of Endocrinology (K.A.T.), 424 General Military Hospital, 54124 Thessaloniki, Greece; Departments of Public Health, Epidemiology, and Biostatistics (K.N., K.H.) and Primary Care Clinical Sciences (R.R., T.M.), University of Birmingham, Birmingham B15 2TT, United Kingdom; and University Hospitals Birmingham National Health Service Foundation Trust (K.N.), Birmingham B15 2TH United Kingdom.
Context:
Evidence suggests that the human skeleton might be involved in the regulation of glucose homeostasis.
Objective:
The objective of the study was to investigate the effect of exposure to bisphosphonates on the risk of incident type 2 diabetes mellitus (T2DM).
Design:
This was a population-based, retrospective, open cohort study over the period 1995-2010.
Setting:
The study was conducted from The Health Improvement Network database from the United Kingdom in a primary care setting.
Patients:
A total of 35 998 individuals aged older than 60 years, without diabetes at baseline and with more than 1 year's exposure to bisphosphonates, and 126 459 age-, gender-, body mass index- and general practice-matched unexposed individuals participated in the study.
Interventions:
There were no interventions.
Main Outcome Measure:
A new diagnosis of T2DM during the 16-year-long observation period, determined by Read codes and adjusted incidence rate ratio in bisphosphonate-exposed compared with unexposed groups, was the main outcome measure.
Results:
The risk of incident T2DM was significantly lower in patients exposed to bisphosphonates compared with matched controls [adjusted incidence rate ratio 0.52, 95% confidence interval (CI) 0.48-0.56, P < .0001]. In subgroup analyses, the findings remained consistent in males [0.77 (95% CI 0.66-0.89)], females [0.49 (95% CI 0.45-0.53)], obese [0.54 (95% CI 0.50-0.59)], individuals exposed to steroid treatment [0.47 (95% CI 0.34-0.64)], and over different types of bisphosphonate medication. Analysis of duration of treatment suggested a brief increase in the risk of T2DM (1 to 2.5 y of exposure), followed by a progressive, sustained decrease as the years of exposure accumulated.
Conclusions:
This observational evidence suggests exposure to bisphosphonates was associated with a significant 50% reduction in the risk of incident T2DM.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Hypoglycemia and Glucagon
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...


